Abliva Past Earnings Performance
Past criteria checks 0/6
Abliva's earnings have been declining at an average annual rate of -11.7%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 18% per year.
Key information
-11.7%
Earnings growth rate
40.3%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -18.0% |
| Return on equity | -51.9% |
| Net Margin | -275,038.7% |
| Next Earnings Update | 23 May 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Abliva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -85 | 14 | 0 |
| 30 Sep 22 | 0 | -105 | 11 | 0 |
| 30 Jun 22 | 0 | -114 | 11 | 0 |
| 31 Mar 22 | 0 | -124 | 12 | 0 |
| 31 Dec 21 | 0 | -123 | 17 | 0 |
| 30 Sep 21 | 2 | -100 | 17 | 0 |
| 30 Jun 21 | 2 | -75 | 16 | 0 |
| 31 Mar 21 | 2 | -65 | 15 | 0 |
| 31 Dec 20 | 2 | -60 | 13 | 0 |
| 30 Sep 20 | 1 | -74 | 15 | 0 |
| 30 Jun 20 | 3 | -79 | 15 | 0 |
| 31 Mar 20 | 4 | -80 | 15 | 0 |
| 31 Dec 19 | 4 | -77 | 15 | 0 |
| 30 Sep 19 | 4 | -65 | 14 | 0 |
| 30 Jun 19 | 2 | -64 | 14 | 0 |
| 31 Mar 19 | 2 | -69 | 15 | 0 |
| 31 Dec 18 | 2 | -68 | 14 | 0 |
| 30 Sep 18 | 2 | -68 | 13 | 0 |
| 30 Jun 18 | 2 | -66 | 13 | 0 |
| 31 Mar 18 | 0 | -63 | 12 | 0 |
| 31 Dec 17 | 0 | -67 | 12 | 0 |
| 30 Sep 17 | 0 | -66 | 14 | 0 |
| 30 Jun 17 | 0 | -87 | 15 | 0 |
| 31 Mar 17 | 0 | -76 | 15 | 0 |
| 31 Dec 16 | 0 | -70 | 15 | 0 |
| 30 Sep 16 | 0 | -63 | 14 | 0 |
Quality Earnings: ABLIS is currently unprofitable.
Growing Profit Margin: ABLIS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ABLIS is unprofitable, and losses have increased over the past 5 years at a rate of 11.7% per year.
Accelerating Growth: Unable to compare ABLIS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ABLIS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: ABLIS has a negative Return on Equity (-51.9%), as it is currently unprofitable.